Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Launches Generic EpiPen At Same Price As Mylan's Generic

Executive Summary

Teva's epinephrine will be the first alternative to branded and authorized generics made by Mylan, but the wholesale acquisition cost of $300 for a two-pack won't be lower.

Advertisement

Related Content

Teva To Launch First Generic EpiPen In 'Coming Months'; FDA Heralds Approval Of Complex Product
EpiPen's Swollen Price May Trigger Patient Assistance Program Probes
Mylan’s EpiPen Exclusivity Saved Again As Teva Reports CRL

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124238

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel